CELL INTELLIGENCE · 肿瘤细胞治疗研究

针对 Wilms 瘤的肿瘤微环境与免疫反应：免疫逃逸机制及其对免疫治疗策略的意义

Tumor Microenvironment and Immune Response Against Wilms Tumor: Evasion Mechanisms and Implications for Immunotherapeutic Approaches.

病例报告：三例异体 CIK 治疗实体瘤

Case Report: Three cases with allogeneic CIK therapy against solid tumors.

Nemvaleukin alfa 单药治疗晚期黑色素瘤和肾细胞癌患者：1/2 期非随机 ARTISTRY-1 试验结果

Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial.

Nemvaleukin 展示了药效学机制验证，在晚期黑色素瘤和 RCC 患者中具有单药抗肿瘤活性和可控的安全性。

肾细胞癌的 CAR-T 细胞治疗：机遇、挑战与新的克服策略

CAR T-cell therapy in renal cell carcinoma: opportunities, challenges, and new strategies to overcome.

Nemvaleukin alfa，一种修饰的白细胞介素-2 细胞因子，作为单药治疗以及与 pembrolizumab 联合治疗晚期实体瘤患者（ARTISTRY-1）

Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1).

Nemvaleukin 耐受性良好，并在经过大量预治疗的晚期实体瘤中显示出有前景的抗肿瘤活性。Nemvaleukin 的 2/3 期研究正在进行中。

一项静脉注射 mitazalimab（一种 CD40 激动型单克隆抗体）治疗晚期实体瘤患者的 1 期研究

A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors.